Targets › PTHR1
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 4; Metabolic and endocrine, Other; next expected readout Nov 2026.
G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, Q03431)
Open in Phaseline: the race on PTHR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Baghdad | Parathyroid Hormone (PTH) Parathyroid hormone receptor 1 agonist; promotes bone formation and osteoblast activity | PTHR1 | Phase 4 | Maxillary Sinus Augmentation | Nov 2026 |
| MBX Biosciences | Canvuparatide PTH analog (parathyroid hormone analog) | PTHR1 | Phase 3 | Hypoparathyroidism | Jan 2028 |
Hypoparathyroidism (1) Maxillary Sinus Augmentation (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.